Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3075% below fair value
$8.07−0.17 (-2.00%)
Close on Nov 13, 2026Market cap $46.69MP/E –Yield –
Xilio Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Xilio Therapeutics's enterprise value was -$80.31M on Nov 11, 2026, against -$64.50M a year earlier. Over the last 5 years it ranged from -$104.02M to $132.30M, with a median of -$41.88M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$80.31M | – |
| 2025 | Dec 31, 2025 | -$70.58M | – |
| 2024 | Dec 31, 2024 | -$19.28M | – |
| 2023 | Dec 29, 2023 | -$44.63M | – |
| 2022 | Dec 30, 2022 | -$60.64M | – |
| 2021 | Dec 31, 2021 | -$77.72M | – |
See a number that looks wrong?